U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute on Drug Abuse (NIDA)<https://www.drugabuse.gov/>
For Immediate Release: Friday, January 5, 2024
CONTACT: NIDA Press Office, <e-mail:media@xxxxxxxxxxxx>,301-443-6245
MEDIA AVAILABILITY
SEMAGLUTIDE ASSOCIATED WITH LOWER RISK OF SUICIDAL IDEATIONS COMPARED TO OTHER TREATMENTS PRESCRIBED FOR OBESITY OR TYPE 2 DIABETES
NIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications
WHAT:
Semaglutide, a highly popular medication approved by the U.S. Food and Drug Administration to treat obesity and manage type 2 diabetes, was associated with a 49% to 73% lower risk of first-time or recurring suicidal ideations compared to other medications for controlling obesity and type 2 diabetes that work via different mechanisms. These findings provide evidence that semaglutide - which helps regulate appetite and insulin levels by targeting glucagon-like peptide 1 receptors (GLP1R) in the body - does not appear to increase the risk of suicidal ideation, contrary to the claims of some anecdotal reports. Published today in Nature Medicine and paired with a related Research Briefing, the study was co-led by scientists at Case Western Reserve University and the National Institute on Drug Abuse (NIDA), National Institutes of Health.
Outside of anecdotal and case reports, this association had not yet been explored by comprehensive studies. Recently, patients prescribed the medication for obesity (brand name Wegovy) or type 2 diabetes (brand name Ozempic), have anecdotally reported suicidal ideations resulting from semaglutide, and this has spurred European regulatory agencies to investigate this potential association.
Researchers examined electronic health records in the United States from 240,618 patients who were obese or overweight (mean age 50 years, 72.6% women) and who were prescribed semaglutide or another medication for weight loss between June 2021 and December 2022. Among this group, 232,771 patients did not have a prior history of suicidal ideation and 7,847 patients did. The researchers also replicated the findings in 1,589,855 patients with type 2 diabetes (mean age 58 years, 49.2% women) who were prescribed either semaglutide or other medications for their condition between December 2017 and May 2021. This group included 1,572,885 patients without and 16,970 patients with a prior history of suicidal ideations. For each study population, the semaglutide groups and the non-GLP1R groups had similarly matched demographic characteristics, medical history, problems with lifestyle, mental and substance use disorders, and prior suicidal ideation and behavior.
Tracking the patients' medical histories through six months after they were prescribed medication, the researchers found people prescribed semaglutide for weight loss had a 0.11% risk of first-time suicidal ideations (among those without a prior history) and approximately a 7% risk of recurrent suicidal ideation (among those with a prior history), compared to 0.43% and 14%, respectively, for the group prescribed other weight loss medications.
In patients with type 2 diabetes, semaglutide prescription was associated with 0.13% risk of first-time suicidal ideations and 10% for recurrent ideation, compared to 0.36% and 18%, respectively, for other diabetes medications. Compared with other medications, semaglutide was also associated with a lower risk of first-time suicidal ideation in patients with type 2 diabetes at longer follow-up durations (up to three years).
The authors concluded that their results do not support concerns of increased suicidal risk associated with semaglutide and highlight the need for a more detailed evaluation of reported cases to date. They recommend future studies evaluate potential longer-term associations of semaglutide with suicidal ideations in patients with obesity or type 2 diabetes - as well as in other at-risk populations - and explore any associations between semaglutide and suicide attempts.
The paper's authorship was also supported by the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Cancer Institute at the NIH.
ARTICLES:
--R Xu, et al. Association of semaglutide with risk of suicidal ideations in a real-world cohort < https://www.nature.com/articles/s41591-023-02672-2>. Nature Medicine. DOI: 10.1038/s41591-023-02672-2 (2023)
--Xu and Volkow. Semaglutide and risk of suicidal ideations <https://doi.org/10.1038/s41591-023-02691-z>. Nature Medicine. DOI: 10.1038/s41591-023-02691-z (2023)
WHO:
Nora D. Volkow, M.D., Director, NIDA
If you or someone you know is in crisis and needs immediate help, call the <https://988lifeline.org/> at 988. Learn more about suicide prevention and ways you can help someone who might be at risk for self-harm.
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <https://www.nih.gov>.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
###
<https://www.nih.gov/news-events/news-releases/glutide-associated-lower-risk-suicidal-ideations-compared-other-treatments-prescribed-obesity-or-type-2-diabetes>
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
